CVRX INC. - COMMON STOCK
14.57
11-فبراير-25 16:45:00
15 متأخرة بدقائق
الأسهم
-0.32
-2.15%
نطاق اليوم
14.39 - 15.08
ISIN
N/A
المصدر
NASDAQ
-
CVRx announces availability of additional data supporting long-term benefits of Barostim
15 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire
-
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
31 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire
-
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
25 يناير 2024 16:05:00 بحسب Nasdaq GlobeNewswire
-
11 يناير 2024 16:30:00 بحسب Nasdaq GlobeNewswire
-
08 يناير 2024 08:30:00 بحسب Nasdaq GlobeNewswire
-
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
27 ديسمبر 2023 16:30:00 بحسب Nasdaq GlobeNewswire
-
CVRx receives FDA approval for expanded labeling of Barostim
26 ديسمبر 2023 08:05:00 بحسب Nasdaq GlobeNewswire
-
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
15 نوفمبر 2023 16:21:43 بحسب Nasdaq GlobeNewswire
-
CMS Increases Outpatient Payment for Barostim Procedure
03 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire
-
CVRx Reports Third Quarter 2023 Financial and Operating Results
26 أكتوبر 2023 16:15:00 بحسب Nasdaq GlobeNewswire
-
12 أكتوبر 2023 16:30:00 بحسب Nasdaq GlobeNewswire
-
CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference
27 يوليو 2023 08:30:00 بحسب Nasdaq GlobeNewswire
-
CVRx Reports Second Quarter 2023 Financial and Operating Results
25 يوليو 2023 16:15:00 بحسب Nasdaq GlobeNewswire
-
11 يوليو 2023 16:30:00 بحسب Nasdaq GlobeNewswire
-
CVRx Set to Join Russell 2000 & 3000 Indexes
22 يونيو 2023 16:30:00 بحسب Nasdaq GlobeNewswire
-
CVRx to Present at the William Blair 43rd Annual Growth Stock Conference
25 مايو 2023 08:30:00 بحسب Nasdaq GlobeNewswire
-
CVRx Reports First Quarter 2023 Financial and Operating Results
27 أبريل 2023 16:15:00 بحسب Nasdaq GlobeNewswire
-
20 أبريل 2023 16:30:00 بحسب Nasdaq GlobeNewswire
-
21 مارس 2023 11:02:23 بحسب Nasdaq GlobeNewswire
-
16 مارس 2023 08:30:00 بحسب Nasdaq GlobeNewswire